About Amendis
Providing a solution to a critical unmet need in
the personalized treatment of Oral Cavity Cancer.
Unmet need in personalized medicine.
Worldwide, head and neck cancers are the sixth leading cancer group by incidence, with approximately 630,000 new patients diagnosed annually, resulting in more than 350,000 deaths every year. Oral cancer is one of the most common types of tumors in the head and neck, while squamous cell carcinomas (SCCs) constitute more than 90% of all oral cancer. Oral SCCs are invasive lesions with a significant recurrence rate that frequently metastasize, where tongue tumors have the greatest tendency of all oral SCCs for metastasis to the neck.
Cervical lymph node metastasis is the single most important prognostic factor in oral cancer, and survival chances are reduced by 50% when compared to those with similar primary tumors without neck metastases. The stage of the oral cancer is determined using the TNM staging system, where T describes the size and depth of the primary tumor, N whether the cancer has spread to the lymph nodes, and M whether the cancer has spread to another part of the body.
Amendis’s solution provides a much more accurate prediction of the future development of head and neck cancer metastasis, and will thus prevent as much as 40% of unnecessary neck surgeries.
